Market Place
Sourcing Support
Foresee Pharma Announces Completion of US$42.1 Million Financing
04 Dec 2024 //
PR NEWSWIRE
Foresee Pharma Submits NDA for 3-Month Camcevi in Prostate Cancer
29 Oct 2024 //
PR NEWSWIRE
Foresee Pharmaceuticals Submits NDA To U.S. Fda For Camcevi
29 Oct 2024 //
PR NEWSWIRE
Foresee Pharmaceuticals Shares Phase 1 Results of Linvemastat
20 Oct 2024 //
PR NEWSWIRE
Foresee Pharma Advances SIF Long-Acting Injectable Technologies
09 Aug 2024 //
PR NEWSWIRE
Foresee Doses First Subject In FP-020 First-In-Human Trial
30 Apr 2024 //
PR NEWSWIRE
Foresee Pharma Poster & Participation at ATS 2024
29 Apr 2024 //
PR NEWSWIRE
Foresee Receives +ve Recommendation to Continue the Ph 3 Trial of Leuprolide
01 Apr 2024 //
PR NEWSWIRE
Foresee Announces Publication of Preclinical Data in the European Heart Journal
08 Nov 2023 //
PR NEWSWIRE
Foresee Pharma to Present at the American Heart Association Annual Meeting
30 Oct 2023 //
PR NEWSWIRE
Foresee Pharmaceuticals Announces First Patient Dosed in the Casppian
13 Oct 2023 //
PR NEWSWIRE
Foresee to Present Phase 1/2 Fanconi Anemia Clinical Study Design for FP-045
30 Sep 2023 //
PR NEWSWIRE
Foresee Announces Publication Demonstrating the Therapeutic Potential of AD-9308
29 Sep 2023 //
PR NEWSWIRE
Foresee Pharmaceuticals Presents Data From its Aderamastat Program at ERS
11 Sep 2023 //
PR NEWSWIRE
Foresee Announces FDA Orange Book Listing of New U.S. Patent for CAMCEVI
29 Aug 2023 //
PR NEWSWIRE
Foresee Selected for Presentation on its Aderamastat Phase 2 Study Results
25 Jul 2023 //
PR NEWSWIRE
Foresee Pharmaceuticals Announces Completion of US$42.3 Million Financing
27 Jun 2023 //
PR NEWSWIRE
FORESEE PHARMACEUTICALS PRESENTED POSTER ON MMP-12 INHBITOR, FP-020
21 Jun 2023 //
PR NEWSWIRE
FORESEE PHARMACEUTICALS ANNOUNCES POSTER PRESENTATION AND PARTICIPATION
16 Jun 2023 //
PR NEWSWIRE
Bassem Elmankabadi, M.D. joins Foresee Pharmaceuticals as a SVP
17 Apr 2023 //
PR NEWSWIRE
Accord Bio, Foresee Pharma Partner to Launch CAMCEVI Injection Emulsion
04 Apr 2022 //
PRNEWSWIRE
Foresee Pharma and TRPharm Announce License and Co-Development Agreement
23 Feb 2022 //
PRNEWSWIRE
Foresee announces potential new COVID-19 drug
06 Jul 2021 //
TAIPEITIMES
Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI® for the Treatment
27 May 2021 //
PRNEWSWIRE
Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI®
26 May 2021 //
PRNASIA
Foresee doses first subject in Covid-19 ARDS treatment trial
29 Mar 2021 //
PHARMACEUTICAL-TECHNOLOGY
Foresee doses first subject in Covid-19 ARDS treatment trial
29 Mar 2021 //
CLINICALTRIALSARENA
Foresee Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025
26 Mar 2021 //
PRNEWSWIRE
Foresee Enters Exclusive License Agreement with Intas Pharmaceuticals
04 Mar 2021 //
PRNASIA
Foresee Enters Exclusive License Agreement with Intas Pharmaceuticals
04 Mar 2021 //
PRNEWSWIRE
Foresee Pharmaceuticals Announces Completion of US$47 Million Financing
23 Dec 2020 //
PRNEWSWIRE
Foresee Pharmaceuticals Announces Completion of US$47 Million Financing
23 Dec 2020 //
PRNASIA
Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci
16 Nov 2020 //
PRNASIA
Foresee Announces NDA for CAMCEVI(TM) 42MG Accepted for Review
09 Oct 2020 //
PRNASIA
Foresee Announces NDA for (TM) 42MG Accepted for Review by the FDA
08 Oct 2020 //
PRNEWSWIRE
Foresee Announces Submission of NDA for FDA Approval of LMIS 50 mg
27 Jul 2020 //
PRNASIA
Foresee Pharma and Accord`s Announce MAA Submission for Camcevi(R) 42mg
30 Mar 2020 //
PRNASIA
Foresee Pharmaceuticals Announces Submission of NDA for FDA Approval of LMIS
29 Mar 2019 //
PR NEWSWIRE
Foresee Pharma announces topline results of FP-001 LMIS in prostate cancer
22 Feb 2019 //
BIOSPECTRUM
Foresee Pharmaceuticals Enters License Agreement with Accord Healthcare
11 Feb 2019 //
PR NEWSWIRE
